Vyome Inc. (HIND)
Vyome Inc. (HIND) Stock Price, Analysis & Data
| Bid | 1.6 |
| Market Cap | 15.93M |
| Revenue (ttm) | 129.72K |
| Net Income (ttm) | -11.31M |
| Beta | n/a |
| EPS (ttm) | -1.56 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 2.63 |
| P/S (ttm) | 122.81 |
| Earnings Date | Nov 13, 2025 |
| Ask | 2.82 |
| Volume | 14,149 |
| Avg. Volume (20D) | 17,050 |
| Open | 2.13 |
| Previous Close | 2.20 |
| Day's Range | 2.13 - 2.30 |
| 52-Week Range | 1.75 - 12.00 |
| Analyst | n/a |
| Price Target | 11.5 (406.61%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HIND
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivit...
Financial Performance
In 2025, Vyome's revenue was 319.71K, an increase of 24.43% compared to the previous year's 256.94K. Earnings were -10.26M, an increase of 608.97%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for HIND stock is "null". The 12-month stock price forecast is 11.5, which is upside of 406.61% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
